Literature DB >> 16012282

Neurologic soft signs in schizophrenic patients treated with conventional and atypical antipsychotics.

Giuseppe Bersani1, Simona Gherardelli, Roberta Clemente, Massimo Di Giannantonio, Alfredo Grilli, Chiara M V Conti, Michael S Exton, Pio Conti, Robert Doyle, Paolo Pancheri.   

Abstract

Neurologic soft signs (NSS) are considered a somatic feature associated with schizophrenia (DSM-IV) that are present in neuroleptic-treated, as well as untreated or first-episode patients. The aim of this study was to determine the incidence and severity of NSS in groups of schizophrenic patients treated with either a conventional neuroleptic medication, haloperidol (n = 37), or atypical antipsychotic medications, risperidone (n = 19), clozapine (n = 34), and olanzapine (n = 18). NSS were assessed with the Neurological Evaluation Scale (NES), whereas extrapyramidal symptoms (EPS), which occur more commonly with conventional neuroleptic treatment, were evaluated using the Simpson-Angus Scale. NES scores were not significantly different between groups. Slight differences were found for 2 items only. The haloperidol group showed higher scores for the "Romberg test," whereas the clozapine group showed higher scores for "short-term memory." There were significant correlations between EPS and NES total score in the haloperidol and risperidone groups. These results demonstrate an overall overlapping of NSS among the groups, confirming their substantial independence from neurologic implications of neuroleptic treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16012282     DOI: 10.1097/01.jcp.0000169268.44421.cf

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  6 in total

1.  Evolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case-Control Trial with Quetiapine.

Authors:  Simon Zhornitsky; Emmanuel Stip; Joelle Desfossés; Tania Pampoulova; Elie Rizkallah; Pierre-Paul Rompré; Lahcen Aït Bentaleb; Olivier Lipp; Jean-Pierre Chiasson; Alain Gendron; Stéphane Potvin
Journal:  Front Psychiatry       Date:  2011-05-13       Impact factor: 4.157

2.  Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: clinical and neuroimaging evidence.

Authors:  Doug Hyun Han; Sun Mi Kim; Jung Eun Choi; Kyung Joon Min; Perry F Renshaw
Journal:  J Psychopharmacol       Date:  2013-01-16       Impact factor: 4.153

Review 3.  Neurological signs and involuntary movements in schizophrenia: intrinsic to and informative on systems pathobiology.

Authors:  Peter F Whitty; Olabisi Owoeye; John L Waddington
Journal:  Schizophr Bull       Date:  2008-09-12       Impact factor: 9.306

4.  Neurological soft signs in schizophrenia: a meta-analysis.

Authors:  Raymond C K Chan; Ting Xu; R Walter Heinrichs; Yue Yu; Ya Wang
Journal:  Schizophr Bull       Date:  2009-04-17       Impact factor: 9.306

5.  Successful ziprasidone monotherapy in a case of delusional parasitosis: a one-year followup.

Authors:  Domenico De Berardis; Nicola Serroni; Stefano Marini; Gabriella Rapini; Alessandro Valchera; Michele Fornaro; Monica Mazza; Felice Iasevoli; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Case Rep Psychiatry       Date:  2013-05-16

6.  Symptomatological features of patients with and without Ecstasy use during their first psychotic episode.

Authors:  Fabio Rugani; Silvia Bacciardi; Luca Rovai; Matteo Pacini; Angelo Giovanni Icro Maremmani; Joseph Deltito; Liliana Dell'osso; Icro Maremmani
Journal:  Int J Environ Res Public Health       Date:  2012-06-27       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.